J M van Rooijen, E G E de Vries. Show Affiliations »
Abstract
Entities: Chemical
Mesh： See more » AgedAntineoplastic Agents/administration & dosageAntineoplastic Agents/pharmacokineticsAntineoplastic Agents/therapeutic useContraindicationsDose-Response Relationship, DrugEverolimusFemaleHumansKidney Failure, Chronic/complicationsKidney Failure, Chronic/therapyLiver Neoplasms/drug therapyLiver Neoplasms/secondaryNeuroendocrine Tumors/drug therapyNeuroendocrine Tumors/pathologyRenal DialysisSirolimus/administration & dosageSirolimus/analogs & derivativesSirolimus/pharmacokineticsSirolimus/therapeutic useTreatment Outcome
Substances： See more » Antineoplastic AgentsEverolimusSirolimus
Year: 2012 PMID： 23135528 DOI： 10.1007/s00280-012-2021-9
Source DB: PubMed Journal: Cancer Chemother Pharmacol ISSN： 0344-5704 Impact factor: 3.333